BioNTech Research and Development, Inc. agreed to acquire substantially all assets from MabVax Therapeutics Holdings, Inc. (OTCPK:MBVX) for $2.3 million on March 20, 2019. The transaction is subject to Bankruptcy Court approval. BioNTech Research and Development, Inc. completed the acquisition of substantially all assets from MabVax Therapeutics Holdings, Inc. (OTCPK:MBVX) on May 8, 2019. The acquisition included MabVax’s antibody assets and infrastructure.